WO2006122186A3 - 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia - Google Patents

1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia Download PDF

Info

Publication number
WO2006122186A3
WO2006122186A3 PCT/US2006/018076 US2006018076W WO2006122186A3 WO 2006122186 A3 WO2006122186 A3 WO 2006122186A3 US 2006018076 W US2006018076 W US 2006018076W WO 2006122186 A3 WO2006122186 A3 WO 2006122186A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxyalkyl
diphenyl
hypercholestrolemia
treating
azetidinone derivatives
Prior art date
Application number
PCT/US2006/018076
Other languages
French (fr)
Other versions
WO2006122186A2 (en
Inventor
Eduardo Martinez
John J Talley
Daniel P Zimmer
Original Assignee
Microbia Inc
Eduardo Martinez
John J Talley
Daniel P Zimmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia Inc, Eduardo Martinez, John J Talley, Daniel P Zimmer filed Critical Microbia Inc
Priority to EP06759488A priority Critical patent/EP1879860A2/en
Publication of WO2006122186A2 publication Critical patent/WO2006122186A2/en
Publication of WO2006122186A3 publication Critical patent/WO2006122186A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The invention relates to a chemical genus of 1,4-diphenyl-3-hydroxyalkyl-2-azetidinones useful for the treatment of hypercholesterolemia and related disorders, having general formula (I).
PCT/US2006/018076 2005-05-10 2006-05-10 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia WO2006122186A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06759488A EP1879860A2 (en) 2005-05-10 2006-05-10 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67932605P 2005-05-10 2005-05-10
US60/679,326 2005-05-10

Publications (2)

Publication Number Publication Date
WO2006122186A2 WO2006122186A2 (en) 2006-11-16
WO2006122186A3 true WO2006122186A3 (en) 2007-03-01

Family

ID=37397271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018076 WO2006122186A2 (en) 2005-05-10 2006-05-10 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia

Country Status (2)

Country Link
EP (1) EP1879860A2 (en)
WO (1) WO2006122186A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US8349814B2 (en) 2006-10-10 2013-01-08 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8957049B2 (en) 2008-04-09 2015-02-17 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9034849B2 (en) 2010-02-03 2015-05-19 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29607A1 (en) 2005-06-20 2007-01-31 Astrazeneca Ab CHEMICAL COMPOUNDS
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
BRPI0715160A2 (en) 2006-08-08 2013-06-11 Sanofi Aventis arylamimoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, drugs comprising these compounds, and their use
WO2008061238A2 (en) * 2006-11-16 2008-05-22 Ironwood Pharmaceuticals, Inc. Processes for production of 4-biphenylyazetidin-2-ones
EP3150589A1 (en) 2007-06-08 2017-04-05 MannKind Corporation Ire-1a inhibitors
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2403848A1 (en) 2009-03-06 2012-01-11 Lipideon Biotechnology AG Pharmaceutical hypocholesterolemic compositions
BR112012003973A2 (en) 2009-08-26 2015-09-08 Sanofi Sa crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
ES2552657T3 (en) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibitors of the recycling of bile acids and satiogens for the treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
US20140243281A1 (en) 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JP2016514684A (en) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー Bile acid recirculation inhibitors for the treatment of primary sclerosing cholangitis and inflammatory bowel disease
BR112015023697A2 (en) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc recycling bile acid inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
EP4245367A3 (en) 2019-02-12 2023-12-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
CN112245421A (en) * 2020-09-25 2021-01-22 北京大学 New application of nemostat in preparation of demethylase inhibitor
CN115068441B (en) * 2022-06-30 2023-04-14 东北农业大学 Water-soluble cannabidiol microcapsule and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMIT BASAK ET AL.: "PPL-catalysed hydrolysis of 3,4-disubstituted beta-lactams: Effect of chain length and stereochemistry on the enantioselectivity", TETRAHEDRON, vol. 54, no. 23, 4 June 1998 (1998-06-04), pages 6529 - 6538, XP004119596 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US8349814B2 (en) 2006-10-10 2013-01-08 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9108989B2 (en) 2006-10-10 2015-08-18 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8957049B2 (en) 2008-04-09 2015-02-17 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US9034849B2 (en) 2010-02-03 2015-05-19 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors

Also Published As

Publication number Publication date
WO2006122186A2 (en) 2006-11-16
EP1879860A2 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2005046603A3 (en) Pyridine compounds
WO2007008529A3 (en) Celullar cholesterol absorption modifiers
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2003093269A3 (en) Substituted pyrazolo-pyrimidine-4-ones
WO2007020103A3 (en) Novel use of peptide compounds for treating muscle pain
EP2518079A3 (en) HCV/HIV inhibitors and their uses
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
SI1881830T1 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006759488

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU